Plasmin-cleaved β-2-glycoprotein 1 is an inhibitor of angiogenesis

American Journal of Pathology

Volumn 171, Issue 5, 2007, Pages 1659-1669

  Sakai, Taro ^a   Balasubramanian, Krishnakumar ^a   Maiti, Sourindra ^a   Halder, Jyotsna B ^a   Schroit, Alan J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; PLASMIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TUMOR GROWTH;

EID: 36348947961     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.070146     Document Type: Article

References (54)

1. Browder T, Folkman J, Pirie-Shepherd S: The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000, 275:1521-1524
2. Rhim TY, Park CS, Kim E, Kim SS: Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth. Biochem Biophys Res Commun 1998, 252:513-516
3. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA: The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997, 94:10868-10872
4. Soff GA: Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000, 19:97-107
5. Steinkasserer A, Estaller C, Weiss EH, Sim RB, Day AJ: Complete nucleotide and deduced amino acid sequence of human β2-glycoprotein I. Biochem J 1991, 277:387-391
6. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R: Crystal structure of human beta 2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999, 18:6228-6239
7. 2-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999, 18:5166-5174
8. Kato H, Enjyoji K: Amino acid sequence and location of the disulfide bonds in bovine beta 2 glycoprotein I: the presence of five Sushi domains. Biochemistry 1991, 30:11687-11694
9. Hunt J, Krilis S: The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994, 152:653-659
10. Hunt JE, Simpson RJ, Krilis SA: Identification of a region of β2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993, 90:2141-2145
11. Wang SX, Cai GP, Sui SF: Intrinsic fluorescence study of the interaction of human apolipoprotein H with phospholipid vesicles. Biochemistry 1999, 38:9477-9484
12. Wang SX, Cai GP, Sui SF: The insertion of human apolipoprotein H into phospholipid membranes: a monolayer study. Biochem J 1998, 335:225-232
13. Hammel M, Schwarzenbacher R, Gries A, Kostner GM, Laggner P, Prassl R: Mechanism of the interaction of beta(2)-glycoprotein I with negatively charged phospholipid membranes. Biochemistry 2001, 40:14173-14181
14. Schousboe I: Binding of β2-glycoprotein I to platelets: effect of adenylate cyclase activity. Thromb Res 1980, 19:225-237
15. Nimpf J, Wurm H, Kostner GM: β2-Glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987, 63:109-114
16. Nimpf J, Wurm H, Kostner GM: Interaction of β2-glycoprotein-I with human blood platelets: influence upon the ADP-induced aggregation. Thromb Haemost 1985, 54:397-401
17. Schousboe I, Rasmussen MS: Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by beta 2-glycoprotein I and anti-β2-glycoprotein I. Thromb Haemost 1995, 73:798-804
18. Schousboe I: β2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985, 66:1086-1091
19. Shi W, Chong BH, Hogg PJ, Chesterman CN: Anticardiolipin antibodies block the inhibition by beta 2-glycoprotein I of the factor Xa generating activity of platelets. [See comments]. Thromb Haemost 1993, 70:342-345
20. Brighton TA, Hogg PJ, Dai YP, Murray BH, Chong BH, Chesterman CN: β2-Glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Br J Haematol 1996, 93:185-194
21. Nimpf J, Bevers EM, Bomans PH, Till U, Wurm H, Kostner GM, Zwaal RF: Prothrombinase activity of human platelets is inhibited by β2-glycoprotein- I. Biochim Biophys Acta 1986, 884:142-149
22. Goldsmith GH, Pierangeli SS, Branch DW, Gharavi AE, Harris EN: Inhibition of prothrombin activation by antiphospholipid antibodies and beta 2-glycoprotein 1. Br J Haematol 1994, 87:548-554
23. Shi T, Iverson GM, Qi JC, Cockerill KA, Linnik MD, Konecny P, Krilis SA: beta(2)-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta(2)-glycoprotein I. Proc Natl Acad Sci USA 2004, 101:3939-3944
24. Ma K, Simantov R, Zhang JC, Silverstein R, Hajjar KA, McCrae KR: High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000, 275:15541-15548
25. Lin KY, Wang HH, Lai ST, Pan JP, Chiang AN: β2-Glycoprotein 1 protects J774A. 1 macrophages and human coronary artery smooth muscle cells against apoptosis. J Cell Biochem 2005, 94:485-496
26. Gomes LF, Alves AF, Sevanian A, Peres CA, Cendoroglo MS, Mello-Almada C, Quirino LM, Ramos LR, Junqueira VB: Role of β2-glycoprotein I. LDL-, and antioxidant levels in hypercholesterolemic elderly subjects Antioxid Redox Signal 2004, 6:237-244
27. Lin KY, Pan JP, Yang DL, Huang KT, Chang MS, Ding PY, Chiang AN: Evidence for inhibition of low density lipoprotein oxidation and cholesterol accumulation by apolipoprotein H (β2-glycoprotein I). Life Sci 2001, 69:707-719
28. Itoh Y, Inuzuka K, Kohno I, Wada H, Shiku H, Ohkura N, Kato H: Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with lupus anticoagulant: measurement with a monoclonal antibody specific for a nicked form of domain V. J Biochem 2000, 128:1017-1024
29. Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG: β2-Glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999, 81:87-95
30. Ohkura N, Hagihara Y, Yoshimura T, Goto Y, Kato H: Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form. Blood 1998, 91:4173-4179
31. Shi T, Giannakopoulos B, Iverson GM, Cockerill KA, Linnik MD, Krilis SA: Domain V of β2-glycoprotein I binds factor XI/XIa and is cleaved at Lys317-Thr318. J Biol Chem 2005, 280:907-912
32. Yasuda S, Atsumi T, Ieko M, Matsuura E, Kobayashi K, Inagaki J, Kato H, Tanaka H, Yamakado M, Akino M, Saitou H, Amasaki Y, Jodo S, Amengual O, Koike T: Nicked beta(2)-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004, 103:3766-3772
33. Cao Y, Cao R, Veitonmaki N: Kringle structures and antiangiogenesis. Curr Med Chem Anticancer Agents 2002, 2:667-681
34. Beecken WDC, Engl T, Ringel EM, Camphausen K, Michaelis M, Jonas D, Folkman J, Shing Y, Blaheta RA: An endogenous inhibitor of angiogenesis derived from a transitional cell carcinoma: clipped β2-glycoprotein-I. Ann Surg Oncol 2006, 13:1241-1251
35. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM: Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997, 57:3325-3330
36. Polz E, Kostner GM: The binding of beta 2-glycoprotein-I to human serum lipoproteins: distribution among density fractions. FEBS Lett 1979, 102:183-186
37. Wurm H: β2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984, 16:511-515
38. Kim JS, Yu HK, Ahn JH, Lee HJ, Hong SW, Jung KH, Chang SI, Hong YK, Joe YA, Byun SM, Lee SK, Chung SI, Yoon Y: Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases. Biochem Biophys Res Commun 2004, 313:534-540
39. McCarty MF, Baker CH, Bucana CD, Fidler IJ: Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol 2002, 21:5-10
40. Demidenko ZN, Vivo C, Halicka HD, Li CJ, Bhalla K, Broude EV, Blagosklonny MV: Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Cell Death Differ 2006, 13:1434-1441
41. Hajjar KA, Jacovina AT, Chacko J: An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994, 269:21191-21197
42. Cesarman GM, Guevara CA, Hajjar KA: An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994, 269:21198-21203
43. Kang HM, Choi KS, Kassam G, Fitzpatrick SL, Kwon M, Waisman DM: Role of annexin II tetramer in plasminogen activation. Trends in Cardiovascular Medicine 1999, 9:92-102
44. Zhang J, McCrae KR: Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2005, 105:1964-1969
45. Colman RW, Schmaier AH: Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997, 90:3819-3843
46. Zhang JC, Claffey K, Sakthivel R, Darzynkiewicz Z, Shaw DE, Leal J, Wang YC, Lu FM, McCrae KR: Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J 2000, 14:2589-2600
47. Kim JS, Chang JH, Yu HK, Ahn JH, Yum JS, Lee SK, Jung KH, Park DH, Yoon Y, Byun SM, Chung SI: Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein (a). J Biol Chem 2003, 278:29000-29008
48. Yu HK, Kim JS, Lee HJ, Ahn JH, Lee SK, Hong SW, Yoon Y: Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles. Cancer Res 2004, 64:7092-7098
49. Doñate F, Juarez JC, Guan X, Shipulina NV, Plunkett ML, Tel-Tsur Z, Shaw DE, Morgan WT, Mazar AP: Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities. Cancer Res 2004, 64:5812-5817
50. Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, Zhang JC, Rabbani SA, McCrae KR, Mazar AP, Morgan WT, Donate F: Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res 2002, 62:5344-5350
51. Olsson AK, Larsson H, Dixelius J, Johansson I, Lee C, Oellig C, Bjork I, Claesson-Welsh L: A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res 2004, 64:599-605
52. Matsuura E, Inagaki J, Kasahara H, Yamamoto D, Atsumi T, Kobayashi K, Kaihara K, Zhao D, Ichikawa K, Tsutsumi A, Yasuda T, Triplett DA, Koike T: Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship. Int Immunol 2000, 12:1183-1192
53. Tuszynski GP, Sharma MR, Rothman VL, Sharma MC: Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc Res 2002, 64:448-462
54. Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH, Hajjar KA: Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004, 113:38-48